Inhaled drug treatment for tuberculosis: Past progress and future prospects

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 127-134

  Hickey, A J ^a   Durham, P G ^a   Dharmadhikari, A ^b   Nardell, E A ^b  

^a RTI INTERNATIONAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Aerosols; Antibiotics; Inhaled therapy; Mycobacterium tuberculosis; Pulmonary drug delivery; Tuberculosis

Indexed keywords

AEROSOLS; ANTIBIOTICS; DRUG DOSAGE; VIRUSES;

CAPILLARY INTERFACES; HUMAN IMMUNODEFICIENCY VIRUS; INHALED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PULMONARY DRUG DELIVERY; RESEARCH COMMUNITIES; TARGET CONCENTRATIONS; TUBERCULOSIS;

DRUG THERAPY;

TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG TARGETING; DRY POWDER INHALER; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MEDICAL DECISION MAKING; NEBULIZER; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANIMAL; FORECASTING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; TREATMENT OUTCOME; TRENDS; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; FORECASTING; HIV INFECTIONS; HUMANS; NEBULIZERS AND VAPORIZERS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84991072031     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.018     Document Type: Article

References (98)

1. [1] Miller, J.B., Abramson, H.A., Ratner, B., Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children. Am. J. Dis. Child. 80:2 (1950), 207–237.
2. [2] Zumla, A., Nahid, P., Cole, S.T., Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12:5 (2013), 388–404.
3. [3] Misra, A., et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb.) 91:1 (2011), 71–81.
4. [4] Hickey, A.J., Montgomery, A.B., Aerosolized pentamidine for treatment and prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Pharmaceutical Inhalation Aerosol Technology, second edition, 2003, Taylor & Francis.
5. [5] Mortensen, N.P., Durham, P., Hickey, A.J., The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. J. Microencapsul. 31:8 (2014), 785–795.
6. [6] Muttil, P., Wang, C., Hickey, A.J., Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26:11 (2009), 2401–2416.
7. [7] Pandey, R., Khuller, G.K., Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55:4 (2005), 430–435.
8. [8] Hanif, S.N.M., Garcia-Contreras, L., Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front. Cell. Infect. Microbiol., 2, 2012, 118.
9. [9] Smith, I., Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16:3 (2003), 463–496.
10. [10] Dannenberg, A.M. Jr., Rook, G.A., Pathogenesis of pulmonary tuberculosis: an interplay of tissue-damaging and macrophage-activating immune responses—dual mechanisms that control bacillary multiplication. Tuberculosis: pathogenesis, protection, and control. Am. Soc. Microbiol. 141 (1994), 1239–1245 (Washington, DC).
11. [11] Liu, P.T., Modlin, R.L., Human macrophage host defense against Mycobacterium tuberculosis. Curr. Opin. Immunol. 20:4 (2008), 371–376.
12. [12] Kaufmann, S., Protection against tuberculosis: cytokines, T cells, and macrophages. Ann. Rheum. Dis. 61:Suppl. 2 (2002), ii54–ii58.
13. [13] Sanders, M., Pulmonary drug delivery: an historical overview. Smyth, H.D.C., Hickey, A.J., (eds.) Controlled Pulmonary Drug Delivery, 2011, Springer, New York.
14. [14] Fernie, W.T., Herbal Simples Approved for Modern Uses of Cure. 2008, Echo Library.
15. [15] Dessanges, J.F., A history of nebulization. J. Aerosol Med. 14:1 (2001), 65–71.
16. [16] Dunbar, C.A., Hickey, A.J., Holzner, P., Dispersion and characterization of pharmaceutical dry powder aerosols. Kona Powder Part. J. 16 (1998), 7–45.
17. [17] Telko, M.J., Hickey, A.J., Dry powder inhaler formulation. Respir. Care 50:9 (2005), 1209–1227.
18. [18] Hickey, A.J., Hickey, A.J., (eds.) Summary of common approaches to pharmaceutical aerosol administration, in Pharmaceutical Inhalation Aerosol Technology, second edition, 2003, Taylor & Francis.
19. [19] Lawlor, C., et al. Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J. Mater. Sci. Mater. Med. 23:1 (2012), 89–98.
20. [20] Gad, S., et al. Preparation and characterisation of novel spray-dried nano-structured para-aminosalicylic acid particulates for pulmonary delivery: impact of ammonium carbonate on morphology, chemical composition and solid state. J. Pharm. Pharmacol. 64:9 (2012), 1264–1274.
21. [21] Vyas, S.P., et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269:1 (2004), 37–49.
22. [22] Sethuraman, V.V., Hickey, A.J., Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech, 3(4), 2002, E28.
23. [23] Parikh, R., Patel, L., Dalwadi, S., Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv. 21:6 (2014), 406–411.
24. [24] Vadakkan, M.V., et al. Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage. Int. J. Nanomedicine 8 (2013), 2871–2885.
25. [25] O'Hara, P., Hickey, A.J., Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 17:8 (2000), 955–961.
26. [26] Hirota, K., et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 142:3 (2010), 339–346.
27. [27] Hirota, K., et al. Distribution and deposition of respirable PLGA microspheres in lung alveoli. Colloids Surf. B: Biointerfaces 105 (2013), 92–97.
28. [28] Suarez, S., et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18:9 (2001), 1315–1319.
29. [29] Garcia-Contreras, L., et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother. 58:5 (2006), 980–986.
30. [30] Ohashi, K., et al. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 135:1 (2009), 19–24.
31. [31] Maretti, E., et al. Inhaled solid lipid microparticles to target alveolar macrophages for tuberculosis. Int. J. Pharm. 462:1–2 (2014), 74–82.
32. [32] Gonzalez-Juarrero, M., et al. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob. Agents Chemother. 56:7 (2012), 3957–3959.
33. [33] Parikh, R., et al. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis. J Antibiot. 67:5 (2014), 387–394 (Tokyo).
34. [34] Rojanarat, W., et al. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int. J. Mol. Sci. 12:7 (2011), 4414–4434.
35. [35] Zhou, H., et al. Hydrophobic ion pairing of isoniazid using a prodrug approach. J. Pharm. Sci. 91:6 (2002), 1502–1511.
36. [36] Yokota, S., Miki, K., Effects of INH (isoniazid) inhalation in patients with endobronchial tuberculosis (EBTB). Kekkaku 74:12 (1999), 873–877.
37. [37] Pham, D.D., et al. Formulation of pyrazinamide-loaded large porous particles for the pulmonary route: avoiding crystal growth using excipients. Int. J. Pharm. 454:2 (2013), 668–677.
38. [38] Durham, P.G., et al. Spray dried aerosol particles of salts for tuberculosis therapy. Mol. Pharm. 12:8 (2015), 2574–2581.
39. [39] Rojanarat, W., et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv. 19:7 (2012), 334–345.
40. [40] Sacks, L.V., et al. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 32:1 (2001), 44–49.
41. [41] Giosue, S., et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 11:1 (2000), 99–104.
42. [42] Raju, B., et al. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect. Immun. 72:3 (2004), 1275–1283.
43. [43] Condos, R., et al. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun. 71:4 (2003), 2058–2064.
44. [44] Grahmann, P.R., Braun, R.K., A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. Int. J. Tuberc. Lung Dis. 12:6 (2008), 636–644.
45. [45] Condos, R., et al. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest 125:6 (2004), 2146–2155.
46. [46] Koh, W.J., et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci. 19:2 (2004), 167–171.
47. [47] Tsurutani, J., et al. A case of multidrug-resistant pulmonary tuberculosis. Nihon Kokyuki Gakkai Zasshi 38:8 (2000), 594–598.
48. [48] Parola, P., Brouqui, P., Clinical and microbiological efficacy of adjunctive salvage therapy with inhaled aminoglycosides in a patient with refractory cavitary pulmonary tuberculosis. Clin. Infect. Dis., 33(8), 2001, 1439.
49. [49] Rikimaru, T., et al. Treatment of ulcerative endobronchial tuberculosis and bronchial stenosis with aerosolized streptomycin and steroids. Int. J. Tuberc. Lung Dis. 5:8 (2001), 769–774.
50. [50] Schoubben, A., et al. Capreomycin inhalable powders prepared with an innovative spray-drying technique. Int. J. Pharm. 469:1 (2014), 132–139.
51. [51] Schoubben, A., et al. Capreomycin supergenerics for pulmonary tuberculosis treatment: preparation, in vitro, and in vivo characterization. Eur. J. Pharm. Biopharm. 83:3 (2013), 388–395.
52. [52] Garcia-Contreras, L., et al. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob. Agents Chemother. 56:5 (2012), 2612–2618.
53. [53] Garcia-Contreras, L., et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51:8 (2007), 2830–2836.
54. [54] Schoubben, A., et al. Simple and scalable method for peptide inhalable powder production. Eur. J. Pharm. Sci. 39:1–3 (2010), 53–58.
55. [55] Verma, R.K., et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob. Agents Chemother. 57:2 (2013), 1050–1052.
56. [56] Roy, C.J., et al. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob. Agents Chemother. 56:2 (2012), 883–886.
57. [57] Wang, C., Hickey, A.J., Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech 11:2 (2010), 538–549.
58. [58] Justo, O.R., Moraes, A.M., Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment. J. Pharm. Pharmacol. 57:1 (2005), 23–30.
59. [59] Park, J.H., et al. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int. J. Pharm. 441:1–2 (2013), 562–569.
60. [60] Hwang, S.M., et al. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Control. Release 129:2 (2008), 100–106.
61. [61] Palazzo, F., et al. Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Int. J. Pharm. 440:2 (2013), 273–282.
62. [62] Sung, J.C., et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother. 53:4 (2009), 1338–1343.
63. [63] Garcia-Contreras, L., et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 54:4 (2010), 1436–1442.
64. [64] Tsapis, N., et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb.) 83:6 (2003), 379–385.
65. [65] Gupta, A., et al. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol. Pharm. 11:4 (2014), 1201–1207.
66. [66] Chan, J.G., et al. A novel inhalable form of rifapentine. J. Pharm. Sci. 103:5 (2014), 1411–1421.
67. [67] Patil-Gadhe, A.A., et al. Rifapentine-proliposomes for inhalation: in vitro and in vivo toxicity. Toxicol. Int. 21:3 (2014), 275–282.
68. [68] Rosas-Taraco, A.G., et al. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 41:2 (2009), 136–145.
69. [69] Chimote, G., Banerjee, R., Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J. Biomed. Mater. Res. A 89:2 (2009), 281–292.
70. [70] Chan, J.G., et al. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur. J. Pharm. Biopharm. 83:2 (2013), 285–292.
71. [71] Ahmad, Z., Sharma, S., Khuller, G.K., Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26:4 (2005), 298–303.
72. [72] Sharma, A., Sharma, S., Khuller, G.K., Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54:4 (2004), 761–766.
73. [73] Pandey, R., Khuller, G.K., Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb.) 85:4 (2005), 227–234.
74. [74] Chan, J.G., et al. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm. Res. 31:5 (2014), 1239–1253.
75. [75] Verma, R.K., et al. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 52:9 (2008), 3195–3201.
76. [76] Sharma, R., et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59:3 (2007), 499–506.
77. [77] Sharma, R., et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18:10 (2001), 1405–1410.
78. [78] Sharma, R., et al. Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis (Edinb.) 91:1 (2011), 107–110.
79. [79] Yadav, A.B., et al. Inhalable microparticles containing isoniazid and rifabutin target macrophages and ‘stimulate the phagocyte’ to achieve high efficacy. Indian J. Exp. Biol. 47:6 (2009), 469–474.
80. [80] Justo, O.R., Moraes, A.M., Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 10:3 (2003), 201–207.
81. [81] Pandey, R., et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52:6 (2003), 981–986.
82. [82] Muttil, P., et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32:2 (2007), 140–150.
83. [83] Manca, M.L., et al. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis. J. Pharm. Pharmacol. 65:9 (2013), 1302–1311.
84. [84] Dharmadhikari, A.S., et al. Phase I, single-dose, dose-escalating study of inhaled Dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 57:6 (2013), 2613–2619.
85. [85] Bhat, M., Hickey, A.J., Effect of chloroquine on phagolysosomal fusion in cultured guinea pig alveolar macrophages: implications in drug delivery. AAPS PharmSci, 2(4), 2000, E34.
86. [86] Stoops, J.K., et al. Certain surfactants show promise in the therapy of pulmonary tuberculosis. In Vivo 24:5 (2010), 687–694.
87. [87] Risin, S.A., et al. Certain surfactants significantly enhance the activity of antibiotics in the mouse model of MTB and drug resistant MTB infection and effectively remove the bacteria from a pulmonary cavity in human ex-vivo study. Ann. Clin. Lab. Sci. 44:2 (2014), 117–122.
88. [88] Lovacheva, O.V., et al. Probl. Tuberk. Bolezn. Legk. 10 (2006), 12–17.
89. [89] Verma, R.K., et al. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis (Edinb.) 93:4 (2013), 412–417.
90. [90] Verma, R.K., et al. Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis. Mol. Pharm. 9:11 (2012), 3183–3189.
91. [91] Burke, G.P., Poochikian, G., Botstein, P., Regulatory science of inhalation aerosols. J. Aerosol Med. 4:3 (1991), 265–268.
92. [92] Niven, R.W., Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12:2–3 (1995), 151–231.
93. [93] Martin, A.R., Finlay, W.H., Nebulizers for drug delivery to the lungs. Expert Opin. Drug Deliv. 12:6 (2015), 889–900.
94. [94] Bohr, A., Beck-Broichsitter, M., Generation of tailored aerosols for inhalative drug delivery employing recent vibrating-mesh nebulizer systems. Ther. Deliv. 6:5 (2015), 223–238.
95. [95] Pulliam, B., Sung, J.C., Edwards, D.A., Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin. Drug Deliv. 4:6 (2007), 651–663.
96. [96] Hickey, A.J., Misra, A., Fourie, P.B., Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J. Pharm. Sci. 102:11 (2013), 3900–3907.
97. [97] Fiegel, J., et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25:4 (2008), 805–811.
98. [98] Geller, D.E., Weers, J., Heuerding, S., Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 24:4 (2011), 175–182.